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Abstract Long-term stable Ba/F3 transfectants (B13Ral and 
B13Roc2) expressing two isoforms of the human I L - l l R a 
receptor ( a l full length or a2 lacking the cytoplasmic domain) 
in combination with human gpl30 were established. IL- l lRod 
and I L - l l R a 2 were each expressed and detected as three bands 
upon Western blot analysis, with apparent molecular masses in 
agreement with those of the polypeptide backbone (47 and 44 
kDa, respectively) with no, one or two N-linked sugars. B13Rocl 
and B13Ra2 bound IL-11-thioredoxin with similar efficiencies 
and proliferated with superimposable dose-response curves to IL-
11, demonstrating that the intracellular domain of I L - l l R a has 
no significant contribution on ligand binding and signaling. 
Analysis of a set of anti-human gpl30 mAbs confirmed the 
similar responsiveness of B13Rocl and B13Rct2 transfectants. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Interleukin-11 (IL-11) is a cytokine produced by a variety 
of cells from mesenchymal origin such as fibroblasts, kerati-
nocytes, chondrocytes, synoviocytes, bone marrow stromal 
cells and osteoblasts. It also displays multiple biological activ-
ities, many of which are similar to those exerted by interleu-
kin-6 (IL-6) and, to a lesser extent, by other pleiotropic cyto-
kines such as L I F (leukemia inhibitory factor), OSM 
(oncostatin M) and C N T F (ciliary neurotrophic factor) [ 1 -
4]. For example, IL-11 and IL-6 act in synergy with IL-3 to 
support the growth of pluripotent bone marrow progenitors 
and to stimulate megakaryogenesis [5]. They both regulate the 
synthesis and secretion of acute-phase proteins by hepatocytes 
[6], promote the differentiation of B lymphocytes into immu-
noglobulin-secreting cells [7], function as adipogenesis inhib-
itory factors [8] and participate in the development of osteo-
clastic cells [9]. The molecular identification of the 
components of the functional high-affinity receptors for these 
pleiotropic cytokines has provided some explanation for this 
redundancy of action. All cytokines of this family require the 
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Abbreviations: IL- l lRa, interleukin-11 receptor; Trx, thioredoxin; 
s-IL-6Ra, soluble IL-6 receptor; mAb, monoclonal antibody 
common gpl30 t ransmembrane glycoprotein to transduce 
their biological activities. The gpl90 glycoprotein (low-affinity 
LIF receptor) is also required for signal transduction through 
LIF , OSM (type I), C N T F and CT-1 receptors [10,11]. 
In the case of the C N T F , IL-6 and IL-11 receptors, addi-
tional receptor components ( a chains) have been described 
which confer cytokine specificity. The C N T F - R a chain is a 
72 k D a glycoprotein (gp72) which is attached to the plasma 
membrane through a glycophosphatidyl inositol (GPI) anchor 
[12]. The IL-6Rcc chain is a 80 k D a membrane anchored gly-
coprotein with a 82 amino acids intracellular domain [13]. 
More recently IL-11 Ret chains have been described in mouse 
[14] and human [15,16]. We have shown the existence of two 
human I L - l l R a cDNAs resulting from alternative exon splic-
ing [15,17]. The first c D N A encodes a t ransmembrane glyco-
protein containing, like the IL-6Rcc chain, a cytoplasmic do-
main (32 amino acids). The second c D N A isoform encodes a 
protein lacking, like the C N T F - R a chain, a cytoplasmic do-
main. In this study, we describe the establishment and char-
acterization of stable Ba/F3 cell lines transfected with the two 
human I L - l l R a isoforms and use these cells to evaluate the 
contribution of the intracytoplasmic domain of I L - l l R a in 
ligand binding and signal transduction. 
2. Experimental procedures 
2.1. Expression constructs 
Human IL-11 cDNA was subcloned into pTrxFus (Invitrogen BV, 
Leek, The Netherlands) to construct a thioredoxin-IL-11 fusion 
cDNA. Expression was performed in E. coli and the fusion protein 
(IL-11-Trx) was prepared as a crude extract from E. coli osmotic 
shock treatment [18]. EcoR\ fragment of BQM15.C cDNA clone 
containing the human IL-11 Reel coding sequence was inserted into 
the pLXSPuro (Transgen) eukaryotic expression vector to obtain 
pLXSP/IL-HRal and selected via the puromycin-resistance gene. Hu-
man IL-l lRa2 complete coding sequence was obtained by PCR am-
plification with the oligonucleotides, 5'-GCGGAATTCATGAGG-
GACCAATGGCAGT and 5'-GGACTTTCTAGATGCTGGCAC, 
using BQP32.21 cDNA clone as template and ligated to the EcoR.1-
Xba\ fragment of BQM15.C cDNA. The sequence of the PCR frag-
ment was confirmed by double-strand DNA sequencing. This insert 
was subcloned in pLXSPuro to obtain pLXSP/IL-HRcc2. 
2.2. DNA transfection experiments 
Ba/F3/gpl30/IL-llRal (B13Ral) and Ba/F3/gpl30/IL-llRa2 
(B13Ra2) were established by electroporating (at 900 uF and 300 
V) mouse pro-B-cell Ba/F3 with 20 ug of pLXSP/IL-HRocl or 
pLXSP/IL-HRa2 and 20 ug of pRCNeo/. Transfected cells were se-
lected in a culture medium containing: RPMI-1640, 10% fetal calf 
serum, 1% glutamine, 0.8 mg/ml G418 (Sigma-Aldrich, St. Quentin 
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Fallavier, France), 5 (ig/ml puromycin (Sigma) and 5 ng/ml (0.25 nM) 
human IL-11. Ba/F3/IL-llRal (BRal), Ba/F3/IL-llRa2 (Bra2) and 
Ba/F3/gpl30 (B13) were obtained using the same procedure except 
that cells were only transfected with one construct and selected in 
medium containing 10% of WEHI-3-conditioned medium as a source 
of IL-3 instead of IL-11 and either 5 ug/ml puromycin (BRal, BRa2) 
or 0.8 mg/ml G418 (B13). 
2.3. Cytokines and monoclonal antibodies 
Human E. coli recombinant IL-11 was from Peprotech Inc. (Lon-
don, UK). IL-6, sIL-6Ra and the anti-IL-6Ra monoclonal antibody 
(mAb) PM1 were kindly given by Dr. Yasukawa (Tosoh Corp., To-
kyo, Japan). The anti-human gpl30 mAbs B-P8, B-S12, B-R3, B-P4 
and the anti-human IL-6Rrx mAb B-N12 were from Diaclone (Besan-
çon, France). Their initial characterisation and analysis of functional 
properties have already been described [19-21]. 
2.4. Proliferation assays 
Transfected Ba/F3 cells were washed twice in culture medium lack-
ing growth factor and seeded in 96-well microtiter plates at a density 
of 15 X 103 cells in 50 JJ.1 per well. In a first type of assay, cells were 
incubated (in a final volume of 100 |il) with serial dilutions either of 
IL-11 (5 nM), of IL-6 (20 nM) in the presence or not of sIL-6Ra 
(fixed concentration of 8 nM), or of a mixture of B-P8 (6.66 nM) plus 
B-S12 (20 nM). In a second type of assay, cells were stimulated with 
IL-11 (0.25 nM) or IL-6 (0.6 nM) plus sIL-6Ra (8 nM), and serial 
dilutions of B-N12 (20 nM), PM-1 (20 nM), B-R3 (20 nM) or B-P4 
(20 nM). Assays were performed in triplicate. After incubation at 
37°C for 36 h, cellular proliferation was assessed by a (4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) based assay 
(Sigma). 
2.5. Flow cytometric analysis 
Cells (1 X105) were preincubated for 3 h in culture medium lacking 
growth factor and washed 3 times. For gpl30 staining, the B-R3 mAb 
was added at a final concentration of 67 nM and incubated on ice for 
1 h. After washing (3 times), cells were stained with a phycoerythrin-
labeled goat anti-mouse antiserum (1:200; Immunotech, Marseille, 
France). For IL- l lRa staining, cells were incubated with IL-11-Trx 
(30 nM), washed 3 times, further incubated for 1 h with a mouse anti-
Trx antibody (1:5000) (Invitrogen), washed again (3 times), and fi-
nally stained with a phycoerythrin-linked goat anti-mouse antiserum 
(Immunotech). In some experiments, a 42-fold molar excess of human 
IL-11 (1.25 uM) was added together with IL-11-Trx. 
2.6. Immunoblot analysis 
Cells were washed 3 times in 10 ml of phosphate-buffered saline 
(PBS) and pelleted by centrifugation. Pellets were frozen (—80°C) and 
thawed once, homogenized in a Dounce homogenizer, and centrifuged 
for 20 min at 2500 rpm at 4°C. The supernatant was centrifuged for 
30 min at 14000 rpm at 4°C. Pellets were resuspended in 10 mM Tris 
buffer (pH 7.4), containing leupeptin at 0.1 mg/ml (Sigma). The pro-
tein concentration was determined by the Bicinchoninic Acid (BCA) 
method (Pierce). Membrane proteins (50 u.g/lane) were resolved by 
10% SDS-PAGE and transferred onto a PVDF membrane (Amer-
sham, Arlington Heights, USA). After blocking, the membrane was 
incubated with a rabbit polyclonal antibody (1:100) directed against a 
20-amino-acid peptide of murine IL-11R (Santa Cruz Biotechnology, 
Santa Cruz, CA). Detection was performed using chemiluminescence 
(ECL kit, Amersham). 
3. Results 
3.1. Generation ofBalFS transfectants with long-term 
proliferation in response to IL-11 
The murine Ba/F3 cell line has been widely used to study 
the reconstitution of cytokine receptors [22]. It is absolutely 
dependent on IL-3 for growth and does not proliferate in 
response to IL-6 or L IF . H u m a n I L - l l R a l or I L - l l R a 2 
cDNAs were transfected in Ba/F3 cells either alone or in 
combination with full-length human gp l30 cDNA. Trans-
fected cells were subsequently cultured in selection media con-
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Fig. 1. Flow cytometric analysis of human gpl30: B-R3 mAb and phycoerythrin-conjugated second antibody (open area). Control: second anti-
body alone (closed area). 
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Fig. 2. Flow cytometric analysis of human IL-llRa: IL-11-Trx/anti-Trx antibody and phycoerythnn-conjugated second antibody in the ab-
sence (thin lane, open area) or presence (thick lane, open area) of a 42-fold molar excess of human IL-11. Control: anti-Trx plus second anti-
body (closed area) 
taining appropriate antibiotic(s) and IL-3 conditioned me-
dium or 5 ng/ml of human recombinant IL-11. In the presence 
of IL-3, cellular expansion was observed in all transfected 
cultures. In IL-11 containing medium, cellular expansion 
was only observed from Ba/F3 cells co-transfected with IL-
l l R a l and gpl30 (B13Rod) or IL- l lRa2 and gpl30 
(B13Roc2). Furthermore, when cells selected in IL-3 condi-
tioned medium were shifted to IL-11 containing medium, 
only cells co-transfected with gpl30 and IL- l lRa l or IL-
11 Ra2 continued to grow, whereas cells transfected without 
insert, with IL-11 Rot 1 alone (BRccl), IL-llRoc2 alone (BRa2) 
or gpl30 alone (B13) rapidly died. These results were consist-
ently obtained in several independent transfection experi-
ments. Long-term proliferation of B13Ral and B13Roc2 
were observed. These cell lines are now routinely grown (for 
more than 6 months) in IL-11 containing medium and retain 
their IL-11 growth-dependency (see Fig. 4A). 
3.2. Analysis of the expression of the transfected receptor 
chains 
Ba/F3 cells expressing different combinations of the trans-
fected cDNAs were established as stable cell lines. The level of 
expression at the cell surface of the transfection products was 
evaluated by flow cytometry and Western blots. Fig. 1 shows 
the flow cytometric histograms obtained with an anti-gpl30 
mAb (B-R3). In contrast to the parental BaF3 cell line which 
was negative, B13, B13Ral and B13Rcc2 expressed gpl30 
with similar intensities. Due to the lack of a suitable anti-
IL-llRcx for flow cytometric analysis, the expression of IL-
l l R a was measured with the combination of an IL-11-thio-
redoxin fusion protein (IL-11-Trx) and an anti-Trx antibody. 
As shown in Fig. 2, both B13Rocl and B13Roc2 transfectants 
were similarly labeled with IL-11-Trx, whereas Ba/F3 and 
B13 cells were negative. The specificity of IL-11-Trx binding 
was assessed by the observation that a 42-fold molar excess of 
unlabeled recombinant IL-11 almost completely inhibited this 
binding. 
Western blots were performed on membrane preparations 
from these different cell lines, using a polyclonal antibody 
raised against a N-terminal peptide of murine IL- l lRa (Fig. 
3). This antibody was negative on parental Ba/F3 cell lines 
and B13 cells and very clearly identified specific bands on IL-
HRa/gpl30 transfected cells. Three bands with molecular 
masses of 47, 50 and 54 kDa were detected on cells transfected 
with the IL- l lRa l isoform, whereas on IL-l lRa2 transfec-
tants, these three bands had lower masses of 44, 47 and 51 
kDa, respectively. 
3.3. Proliferative responses 
We next examined the proliferative response of the various 
transfectants to different cytokines. All cell lines proliferated 
in response to IL-3-conditioned medium with comparable 
dose responses (data not shown). Only IL-llRa/gpl30 dou-
ble-transfected cells did proliferate in response to IL-11 (Fig. 
4A), showing that both IL- l lRa and gpl30 are required and 
sufficient for IL-11 signaling in Ba/F3 cells. The dose-response 
curves relative to the effects of IL-11 on the B13Ral and 
B13Ra2 proliferative responses were almost superimposable, 
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B-P4 antibody abbrogated the IL-11 response in B13Rod and 
B13Ra2 cell lines with a similar efficacy as B-R3 (ICsos = 0.24 
and 0.18 nM) (Fig. 5G). Unexpectedly, the B-P4 antibody 
also abbrogated the IL-6/sIL-6Roc proliferative effect on the 
two cell lines (IC50s = 0.43 and 0.47 nM) (Fig. 5H). 
4. Discussion 
Fig. 3. Western blot analysis of human IL-l lRa. Molecular weight 
markers (left) are in kDa. 
This study shows that co-expression in the Ba/F3 cell line of 
the human IL-11 Rot with human gpl30 is necessary and suf-
ficient for the acquisition of human IL-11 mediated prolifer-
ative response and for the establishment of Ba/F3 cell trans-
fectants which can be grown on a long-term basis under the 
growth promoting effect of recombinant human IL-11. These 
transfectants are now grown in our laboratory for more than 
6 months without any significant changes of their IL-11 
growth response sensitivities. These results extend recent ob-
thereby indicating that the two isoforms have comparable 
efficiencies in complementing gpl30 for signaling. The concen-
tration of IL-11 inducing half maximal proliferative responses 
(IC50) were 97 and 118 pM, respectively, values compatible 
with a high-affinity interaction. 
The responses of these two double transfectants to the com-
bination of IL-6 plus sIL-6Roe were also comparable (Fig. 
4B), a result further indicating that the two cell lines express 
equivalent amounts of functional human gpl30. The IC50S for 
IL-6 in the presence of a fixed concentration of sIL-6Roc (8 
nM) were 66 and 75 pM, respectively, values in agreement 
with its high-affinity equilibrium binding constant [23]. We 
also tested two anti-human gpl30 mAbs (B-P8 and B-S12) 
which have been described to display synergistic and agonistic 
functions [19]. In agreement with these findings, B-P8 plus B-
S12 induced the proliferation of B13Rccl and B13Roc2 trans-
fectants (Fig. 4C) with efficiencies comparable to those in-
duced by IL-11 or IL-6/sIL-6Ra. Again, the responses of 
the two transfectants were superimposable, with IC50S of 
0.38 and 0.41 nM. 
IL-11 versus IL-6/sIL-6Ra proliferative responses of the 
two transfectants were further assessed by the use of addi-
tional monoclonal antibodies (Fig. 5). B-R3 is an anti-human 
gpl30 mAb which interferes with the biological effects of all 
known cytokines using gpl30 as transducing element, whereas 
B-P4 is an anti-gpl30 mAb which has been proposed to in-
terfere specifically with the IL-11 response [19-21]. PM1 and 
B-N12 are anti-human IL-6Roc mAbs. PM1 is a blocking anti-
body [24], whereas B-N12 is not (J. Wijdenes, unpublished 
result). For each mAb tested, the responses of B13Rocl and 
B13Ra2 were always almost superimposable. The B-N12 anti-
body had no effect in either system (Fig. 5A,B). The PM1 
mAb inhibited the IL-6/sIL-6Roc responses (IC5os: 6.3 and 
7.5 nM) (Fig. 5D) while only slightly diminishing the IL-11 
driven proliferation (Fig. 5C). The proliferation induced by 
either IL-11 or IL-6/sIL-6Roc was totally abbrogated by mAb 
B-R3 (Fig. 5E,F). The IC50s describing the inhibitory effects 
on IL-11 were 0.30 and 0.24 nM, and those on the IL-6 
response were 0.44 and 0.41 nM. These values are in full 
agreement with the binding affinity of B-R3 on these cells as 
measured by Scatchard analysis (K^ = 0.43 and 0.49 nM on 
B13Rotl and B13Ra2 cells respectively; data not shown). The 
1.4 
1.2 
I l 
o 0.8 
in 
Q 0.6 
° 0.4 
0.2 
0 
0.001 0.01 0.1 1 
IL-11 (nM) 
[ ■ 1 111 n n j — - T - r T T m r r ™ - - T T T T T T ] 1 M I I IUJ 
+ SIL-6R0C (8nM) 
I I I 1 l I I 
0.001 0.01 0.1 1 
IL-6 (nM) 
10 
0.01 0.1 1 10 
(B-P8 + B-S12)(nM) 
Fig. 4. Proliferative responses of B13Ral (•) and B13Ra2 (o) cells. 
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Fig. 5. Effects of anti-gpl30 and anti-IL-6R mAbs on B13Ral (•) and B13Ra2 (o) proliferative responses induced either by IL-11 (5 nM) 
(left) or by IL-6 (0.6 nM) plus sIL-6Ra (8 nM) (right). 
servations on similarly co-transfected Ba/F3 cells showing that 
IL-11 was able to maintain cell viability on a short (48 h) time 
period [14,16] and provide for the first time the description of 
stable human IL-1 IRa/gp 130 Ba/F3 cell transfectants prolif-
erating in response to human IL-11. 
We have previously shown that the human IL-11 Roc chain 
exists in two different isoforms resulting from alternative 
splicing of a single gene. These two naturally occurring IL-
U R a isoforms differ only by the presence of the 32-amino-
acids cytoplasmic domain [15]. We took advantage of this 
situation to analyze the functional implication of this cyto-
plasmic domain in the Ba/F3 system. 
A polyclonal antibody raised against the N-terminal peptide 
(residues 25^14) of mouse IL-11 Ret was shown to react with 
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human IL- l lRa in Western blot. This could be expected from 
the high degree of amino-acid sequence homology (95%) 
found in this region between mouse and human receptors 
[15]. This antibody enabled us to document for the first 
time the biochemical features of the human IL-11 Roc chain. 
It reacted with three bands of molecular masses of 47, 50 and 
54 kDa on the B13Ral cells and with three bands of molec-
ular masses of 44, 47 and 51 kDa on the B13Roc2 cells. This 
pattern is consistent both with the predicted molecular masses 
of the mature proteins encoded by the human IL- l lRa l and 
IL-l lRa2 cDNA isoforms, which are respectively 43 100 and 
39800 Da, and with the existence within the extracellular 
domain of the human IL- l lRa of two potential N-glycosyla-
tion sites [15]. Thus, for each receptor isoform, the lower band 
likely corresponds to the unglycosylated species, whereas the 
upper bands would correspond to glycosylated species con-
taining one or two N-linked sugars, respectively. Indeed, the 
increments in molecular mass from the lower to the upper 
band are in the range of 3^1 kDa, values consistent with 
the average molecular mass of 2800 Da calculated for a com-
plex N-linked carbohydrate [25]. When comparing the two 
receptor isoforms, the difference in molecular masses between 
two paired bands is about 3 kDa, a value compatible with 
that predicted from the difference in amino acids (32 amino 
acids; 3500 Da). 
The two B13Rccl and B13Ra2 cell lines expressed similar 
amounts of the human gpl30 signal transducer as revealed by 
flow cytometry. They were also similarly able to bind the 
fusion protein IL-11-Trx. When the proliferative responses 
to human IL-11 were compared, the two transfectants were 
found to display nearly superimposable dose responses with 
high affinity (IC50 around 100 pM). Taken together, these 
data strongly suggest that, at least in the Ba/F3 transfection 
system, both IL- l lRa isoforms similarly conjugate with 
gpl30 to bind IL-11 and transduce a proliferative signal. 
The intracellular domain of the human IL- l lRa chain seems 
therefore dispensable for binding to and signaling through the 
receptor complex in this cellular system. 
In the case of the IL-6 receptor, homodimerisation of the 
gpl30 subunit has been shown to be the key event in signal 
transduction and the IL-6Ra cytoplasmic domain is consid-
ered to play no role in the signaling process. This concept is 
based on the observations that soluble forms of the extracel-
lular domain of IL-6Ra can combine with IL-6 and gpl30 to 
trigger the signaling event, and that the intracellular domain 
of IL-6Ra lacks characteristic sequence motifs required for 
signaling [26]. However, analysis of the function of the IL-
6Ra in hepatoma cells has indicated that, whereas its cyto-
plasmic domain is not absolutely required for signal trans-
duction (C-reactive protein promoter activation), the last 40 
amino acids of this domain contribute to maximal IL-6 re-
sponse [27]. Similarly, soluble form of the mouse IL- l lRa 
chain were found to be less effective than the membrane 
form in hepatoma cells, embryonal carcinoma cells and T 
lymphocytes [28], suggesting an auxiliary function for the 
membrane and/or cytoplasmic domains. Our present results 
with the human IL-11 receptor system in Ba/F3 cells clearly 
demonstrate that the intracellular domain has no influence on 
the efficiency of signaling. 
Various anti-gpl30 mAbs have already been described and 
analysed for their ability to interfere with the biological activ-
ities mediated by cytokines using the gpl30 transducing sub-
unit. Among them are the B-P8 and B-S12 mAbs which have 
been shown to display agonistic and synergistic activities on 
XG1 myeloma and TF1 erythroleukemia cell lines and on 
stem cells [19]. Our data show that this agonistic activity is 
also observed in Ba/F3 cells transfected with gpl30, confirm-
ing these previous findings. The B-R3 mAb was shown to 
inhibit the growth promoting activity of IL-6, CNTF, LIF 
and OSM on the XG4-CNTF myeloma cell line as well as 
the growth inducing effect of IL-11 on the XG-6-IL-11 mye-
loma cell line [19,21]. This mAb also inhibited the growth 
promoting effects of all these cytokines, also including CT-1, 
on the TF1 cell line and haptoglobin secretion induced by IL-
6 and OSM on hepatoma HepG2 cells [20]. In agreement with 
these observations, B-R3 was found in this study to inhibit the 
proliferation of the two IL- l lRa transfectants induced either 
by IL-11 or the combination of IL-6 plus sIL-6Ra. The in-
hibitory capacities of B-R3 on the IL-11 or IL-6 signals were 
similar (IC50 around 0.3 nM and 0.4 nM, respectively) and in 
agreement with its binding constant (K& around 0.45 nM) on 
both cell types. This observation supports the notion that B-
R3 is not a competitive inhibitor of cytokine binding but 
rather interferes with a region of gpl30 important for its 
dimerisation. B-P4 is another anti-human gpl30 mAb which 
has been described to specifically inhibit (with respect to other 
cytokines) the IL-11 induced proliferative response of myelo-
ma cell lines [19] and TF1 cells [20]. This antibody was indeed 
found in this study to be as efficient as B-R3 in inhibiting the 
IL-11 responses of B13Ral and B13Ra2 transfectants (IC5o 
around 0.2 nM). However, it also inhibited the proliferation 
of these transfectants in response to IL-6 plus sIL-6Ra with 
an efficiency again comparable to that of B-R3 (IC50 around 
0.45 nM). As a control, the anti-IL6Ra mAb PM1 only af-
fected the IL-6 response. These results therefore suggest that 
on transfected Ba/F3 cells, the epitope defined by B-P4 might 
be used in common by the IL-11/IL-llRa and IL-6/IL-6Ra 
complexes to activate signal transduction. The discrepancy of 
our findings with previous observations [19-21] might be 
linked to the fact that we used a soluble form of IL-6Ra, 
whereas the other reports were dealing with membrane-anch-
ored IL-6Ra. It could also reflect differences in sensitivity 
among various IL-6-induced biological responses to the block-
ing effect of B-P4. This discrepancy might also indicate that 
the conformations of the reconstituted receptors in Ba/F3 cells 
differ in some way with those of natural receptors constitu-
tively expressed by cell lines. However it may be, elucidation 
of this apparent discrepancy deserves further investigations. 
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